Association Of Anti-pre S1 Antibody And Early Response To Interferon In The Protein With Chronic Hepatitis B

Objective To improve the individual therapy of interferon by investigating the relationship between anti-pre-S1 antibody (anti-PreS1) and early response to interferon treatment in the patients with chronic hepatitis B.Methods Interferon treatment of 69 cases of chronic hepatitis B patients were studied prospectively, including 42 cases using the normal interferon,27 cases using polyethylene glycol interferon. The anti-PreS1 was detected in serum by enzyme-linked immunosorbent assay (ELISA). Early response to interferon was evaluated following up for 12 weeks based on the viral load, alanine amino transferase (ALT) and serum markers of hepatitis B virus (HBV). According to the reactivity of anti-PreS 1,69 patients with chronic HBV infection were divided into anti-PreS1 positive group and anti-PreS1 negative group, to evaluate the difference between the two groups to interferon therapy. All data analysis was carried out using SPSS 13.0 statistical software.Results Both groups of anti-PreS1 positive (21 cases) and negative (48 cases) showed no significant difference in interferon species. The HBV DNA levels and ALT values in anti-PreS1 positive group were significantly lower than those in anti-PreS1 negative group after early interferon treatment for 12 weeks, and furthermore, the HBeAg negative rate and seroconversion rate in anti-PreS1 positive group were higher than those in anti-PreS1 negative group, suggesting that the circulating anti-PreS 1 was associated with the viral load, ALT decline, and changes of serum HBeAg.Conclusion The appropriate chronic hepatitis B patients can be screened by examining anti-PreSl before the treatment for the better individual therapy of interferon.